Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 19, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 3, 2022 at 8:00 a.m.
View HTML
Toggle Summary Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
Data to be Presented During the Emerging Science Session at the American Academy of Neurology’s 74th Annual Meeting The LUMINARY Study is a Phase 2, open-label study evaluating the safety, tolerability and efficacy of SAGE-718 once daily in individuals with mild cognitive impairment and mild
View HTML
Toggle Summary Sage Therapeutics to Present at 2022 Stifel CNS Days
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the 2022 Stifel CNS Days on Tuesday, March 29, 2022 at
View HTML
Toggle Summary Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
Data Presented at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders The PARADIGM Study is a Phase 2, open-label study evaluating the safety, tolerability, and efficacy of SAGE-718 once daily in
View HTML
Toggle Summary Sage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will
View HTML
Toggle Summary Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
Rolling NDA submission for zuranolone in MDD expected to begin in early 2022 and planned to be completed in the second half of 2022 now supported by data from six positive clinical studies An associated NDA submission in PPD expected in 2023; Fast Track designation received for zuranolone in PPD
View HTML
Toggle Summary Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms Key secondary endpoint demonstrates zuranolone co-initiated with an antidepressant was statistically significant in reducing
View HTML
Toggle Summary Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 10, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2022-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present
View HTML
Toggle Summary Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
In the open-label LUMINARY Study, SAGE-718 improved performance from baseline on multiple tests of cognitive function in patients with Alzheimer’s disease mild cognitive impairment and mild dementia, consistent with positive signals seen in Parkinson’s disease and Huntington’s disease Now enrolling
View HTML